|
Delphi Bio Team and Partners Delphi Bio was founded by two thought leaders in the commercial arena of the biotechnology industry. The company was founded to serve the unmet need of providing consultants who have worked for cutting edge biotechnology companies and developed detailed commercialization plans in competitive environments to companies that are seeking to gain a competitive edge. Delphi is able to identify, assess, and suggest strategies that will capture market share in new, and current, areas. Contact Us For a Proposal on Your Project: information@delphibio.com JOHN BOYCE John recently served as Head of Business Development for Helicos BioSciences, where he was responsible for identifying new market opportunities in which the company was able to develop new applications that gave it a substantial competitive advantage. As a result of this effort, John was able to identify both a market, as well as form a collaborative effort to develop an application, that allowed the company to go public in May 2007. Despite the competitive landscape in the next generation DNA sequencing market and unfavorable market IPO conditions, the company was able to raise $48.6MM and obtain top level banking institutes such as J.P. Morgan, UBS, Pacific Growth equities, and Leerink Swann. Prior to Helicos, John was the Senior Director of Commercial Development for Parallele Biosciences, Inc. He played an integral role of building the company and orchestrating the sale of the company to Affymetrix within two years after the companies had formed a co-marketing agreement. He was also the Senior Director of Business Development for Genomics Collaborative where he was responsible for putting in place and building the Sales, Marketing, and Business Development infrastructure. John executed several key deals and played a vital role in the sale of the company to SeraCare Life Sciences, Inc. Prior to Genomics Collaborative, John served a distinguished and successful tenure as Director, United States Sales at Sequenom Inc., from FY 2000 to FY 2003 where he led the successful expansion of Sequenom's MassARRAY system and consumable business in the United States. John was also responsible for designing and executing a strategic sales and marketing initiative, which paved the path for entry into various key market segments and in total generated over 28MM in revenue for the company. Jessica has been successful in a wide variety of disciplines from direct selling and product management to strategic marketing, business plan development and integration, and marketing communications. Most recently, while at Affymetrix, Jessica successfully managed the Affymetrix >$100M DNA product line. Notably, Jessica led the efforts for the successful launch of the SNP6.0 product. Impact of this successful product launch has been documented by analysts from UBS, PacGrow, Deutsche Bank and PiperJaffrey. In her five year tenure at Affymetrix. Jessica held multiple positions in both the marketing and sales organizations. These roles include a management position leading the DNA product marketing group, a market development position influencing strategic sales and a tactical marketing position leading product launches. Jessica has been widely quoted as an expert in the biotechnology field in journals such as Nature, Science, and Genome Technologies. In 2000, she joined Sequenom, which at the time was a small biotechnology company (<50 individuals). She performed direct sales for the new and emerging technology helping to seed the market as one of the first SNP technologies. Jessica has a wide rolodex of industry contacts and a variety of experience in sales and marketing. |
